PEGS_Banner_Antibodies-Cancer


The outlook for therapeutic antibodies is very promising. This meeting will highlight current trends in development including identifying and validating novel targets, improving drug-like properties, employing immunotherapy approaches and advancing novel constructs. This program has consistently recruited top thought leaders in the field to review the status of myriad innovative antibodies and key ideas for advancing them towards the clinic.


PLENARY KEYNOTE SESSION

How to Best Launch a New Platform

Tillman U. Gerngross, Ph.D., Professor, Engineering; Associate Provost, Entrepreneurship & Technology Transfer, Thayer School of Engineering at Dartmouth; Co-Founder and CEO, Adimab

Targeting Cancer Stem Cells

Robert A. Weinberg, Ph.D., Member, Whitehead Institute for Biomedical Research; Professor, Biology, Massachusetts Institute of Technology


ANTIBODIES FOR IMMUNOTHERAPY
What Are the Challenges and How Do We Overcome Them? 

KEYNOTE PRESENTATION: Talk Title to be Announced

Bahija Jallal, Ph.D., Executive Vice President, MedImmune

Human Anti-CCR4 mAb Reverses Immunosuppression and Restores Anti-Tumor Immunity

Wayne A. Marasco, M.D., Ph.D., Professor, Medicine, Harvard Medical School

Intratumoral Gene-Therapy with IL-12 to Enhance Responses to Immune “Checkpoint” Therapy

Robert H. Pierce, M.D., CSO, OncoSec Medical, Inc.

Biomarker Development in Immune Therapies for Oncology

Jennifer H. Yearley, D.V.M., Ph.D., DACVP, Principal Scientist, Profiling and Expression, Merck Research Laboratories

Combination Therapy

F. Stephen Hodi, M.D., Director, Melanoma Disease Center & Center for Immuno-Oncology, Dana-Farber Cancer Institute

Program on PDL1

Helen Sabzevari, Ph.D., Global Head, Oncology & Immunotherapy, EMD Serono Research Institute

KEYNOTE PRESENTATION: Antibody Targeted Cancer Immunotherapy

Louis M. Weiner, M.D., Director, Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Identification and Translation of Optimal Immunotherapy Combinations

Michael A. Curran, Ph.D., Assistant Professor, Immunology, University of Texas MD Anderson Cancer Center


ADCS AND BISPECIFICS

A Novel Calicheamicin-Based ADC for Solid Tumors

Marc I. Damelin, Ph.D., Senior Principal Scientist, Oncology Research Unit, Pfizer, Inc.


ANTIBODIES TO WATCH: PHASE III CLINICAL TRIALS

Patritumab- anti-HER3 mAb for Non-Small Cell Lung Cancer (NSCLC)

Robert A. Beckman, M.D., Executive Director, Clinical Development Oncology, Daiichi Sankyo Pharmaceutical Development


EMERGING TARGETS AND TECHNOLOGIES

KEYNOTE PRESENTATION: Mesothelin: An Important Target for Cancer Immunotherapy

Ira Pastan, M.D., NIH Distinguished Investigator, Co-Chief, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health

Emerging Immune Checkpoint Targets for Cancer Immunotherapy

Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology Medicine, Albert Einstein College of Medicine

Single-Domain Antibodies from Sharks: Utility and Basic Science

Martin F. Flajnik, Ph.D., Professor, Microbiology and Immunology, University of Maryland, Baltimore



For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5464
E: clingham@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com